PCN10 COST-EFFCTIVENESS ANALYSIS OF ERLOTINIB COMPARED WITH DOCETAXEL AND PEMETREXED FOR SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN TAIWAN
Abstract
Authors
TC Hsia GC Chang YM Chen MC Lin WC Su CM Tsai L Yang J Creeden